CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) reported today that it presented positive preclinical data on the pharmacology and mechanism of action of Solazed (MIP-1145), its targeted radiotherapeutic candidate for the detection and treatment of metastatic melanoma, at the Society of Nuclear Medicine’s (SNM) 55th Annual Meeting in New Orleans. The company performed a series of studies to identify a lead radiotherapeutic candidate from a library of compounds. MIP-1145 was selected for entry into clinical trials based on its significant melanin-specific tumor uptake and retention in vitro and in vivo, anti-tumor activity and radiochemical stability and solubility profile. Molecular Insight plans to begin a Phase 1 dosimetry trial for Solazed later this year.
